Literature DB >> 16873439

Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?

T Van den Wyngaert1, M T Huizing, J B Vermorken.   

Abstract

BACKGROUND: An increasing amount of reports are being published suggesting a relationship between the use of bisphosphonates (BPs) and the development of osteonecrosis of the jaw (ONJ). We reviewed the currently available evidence and explore the potential mechanisms of action based on the known effects of the concerned BP.
DESIGN: The MEDLine, Current Contents and Science Citation Index Expanded databases were queried and the results augmented by analyzing cited references and recent congress proceedings.
RESULTS: 22 papers were included detailing 225 patients, all based on retrospective chart review without control groups. The prevalence of ONJ was estimated at 1.5%. The involved BPs were pamidronate, zoledronic acid, alendronate and risedronate, all potent nitrogen-containing agents. The most common symptom was pain (81.7%), although 12.2% of cases were asymptomatic. In 69.3% of patients ONJ was preceded by a dental extraction. At the time of diagnosis, 74.5% of patients were receiving chemotherapy and in 38.2% of cases corticosteroids were administered. Although various conservative and surgical treatment modalities were reported, residual sites of ONJ persisted in 72.5% of cases.
CONCLUSION: Although not enough evidence is available to prove a causal link, it seems that under specific circumstances local defenses can become overwhelmed resulting in ONJ.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16873439     DOI: 10.1093/annonc/mdl294

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  27 in total

Review 1.  Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review.

Authors:  Sabrina Crépin; Marie-Laure Laroche; Bernard Sarry; Louis Merle
Journal:  Eur J Clin Pharmacol       Date:  2010-05-01       Impact factor: 2.953

2.  RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?

Authors:  Tim Van den Wyngaert; Kristien Wouters; Manon T Huizing; Jan B Vermorken
Journal:  Support Care Cancer       Date:  2011-01-04       Impact factor: 3.603

3.  Bisphosphonates induce senescence in normal human oral keratinocytes.

Authors:  R H Kim; R S Lee; D Williams; S Bae; J Woo; M Lieberman; J-E Oh; Q Dong; K-H Shin; M K Kang; N-H Park
Journal:  J Dent Res       Date:  2011-03-22       Impact factor: 6.116

Review 4.  Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.

Authors:  J Chang; A E Hakam; L K McCauley
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

5.  Efficacy of pamidronate in children with low bone mineral density during and after chemotherapy for acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Authors:  Jae Min Lee; Ji Eun Kim; Soon Hwan Bae; Jeong Ok Hah
Journal:  Blood Res       Date:  2013-06-25

Review 6.  [Bisphosphonates for malignant bone tumors].

Authors:  G Holzer
Journal:  Orthopade       Date:  2009-04       Impact factor: 1.087

Review 7.  Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature.

Authors:  Jan Rustemeyer; Andreas Bremerich
Journal:  Clin Oral Investig       Date:  2009-06-04       Impact factor: 3.573

8.  Tooth extraction in osteoporotic patients taking oral bisphosphonates.

Authors:  M Mozzati; V Arata; G Gallesio
Journal:  Osteoporos Int       Date:  2013-01-04       Impact factor: 4.507

9.  Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats.

Authors:  Akishige Hokugo; Shuting Sun; Sil Park; Charles E McKenna; Ichiro Nishimura
Journal:  Bone       Date:  2012-12-04       Impact factor: 4.398

Review 10.  Pathophysiology of Osteonecrosis of the Jaws.

Authors:  Tara Aghaloo; Renna Hazboun; Sotirios Tetradis
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2015-09-26       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.